Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 6/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849191 | 0.84 | FLT3 (0.65) | FLT3ATR | |
| SCHEMBL13849202 | 0.84 | FLT3 (0.61) | FLT3ATRCHEK1 | |
| SCHEMBL13849263 | 0.82 | FLT3 (0.56) | BRD4FLT3ATRCHEK1 | |
| SCHEMBL31172494 | 0.82 | FLT3 (0.73) | FLT3CHEK1 | |
| SCHEMBL1645627 | 0.75 | BCHE (0.66) | BCHEBRD4FLT3CYP1A2 | |
| SCHEMBL13849194 | 0.74 | FLT3 (0.47) | FLT3CHEK1 | |
| SCHEMBL4096515 | 0.74 | FGFR1 (0.54) | BRD4CYP1A2CHEK1 | |
| SCHEMBL8329416 | 0.73 | BCHE (0.66) | BCHECYP1A2 | |
| SCHEMBL4640990 | 0.73 | BCHE (0.87) | BCHEBRD4 | |
| SCHEMBL4097487 | 0.72 | CHEK1 (0.51) | BRD4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1891048-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | Vernalis (R&D) Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006134318-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | BCHE 3137/4885BRD4 364/4885FLT3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.